Semaglutide: A Research Reference Guide to the GLP-1 Receptor Agonist
By Lemon Labs Research Desk · Updated June 29, 2026
In short
Semaglutide is a synthetic peptide that selectively agonizes the glucagon-like peptide-1 (GLP-1) receptor. Its structure is engineered for an extended half-life, making it a long-acting GLP-1 analog widely used as a reference compound in incretin research. It is research-use-only.
What is semaglutide?
Semaglutide is a GLP-1 receptor agonist — a peptide analog of the naturally occurring incretin hormone GLP-1. It carries structural modifications, including a fatty-acid chain, that resist enzymatic degradation and prolong its action in pharmacokinetic studies, which is why it is described as long-acting.
GLP-1 signaling in research
The GLP-1 receptor is a G-protein-coupled receptor expressed in numerous tissues. In research models, GLP-1 agonism is studied for glucose-dependent effects on insulin signaling and for receptor expression patterns across cell types. Semaglutide serves as a standard single-receptor agonist against which dual agonists like tirzepatide are often compared.
Handling and quality
Supplied lyophilized; store cold and sealed, protected from light, and reconstitute in the lab. Verify ≥99% HPLC purity and mass-spec identity on the lot COA before experimental use.
Research-use-only statement
This compound is supplied strictly for in-vitro research and laboratory use. It is not a drug, supplement, food, or cosmetic, has not been evaluated by the FDA, and is not intended to diagnose, treat, cure, or prevent any disease. It is not for human or veterinary use. All information here summarizes published scientific literature for educational purposes for qualified researchers — it is not medical advice and does not describe human administration.
Reference compounds mentioned
Frequently asked
What receptor does semaglutide target?
Semaglutide selectively agonizes the GLP-1 receptor, a G-protein-coupled receptor central to incretin signaling research.
Why is semaglutide called long-acting?
Structural modifications, including a fatty-acid chain, slow its enzymatic degradation and extend its half-life in pharmacokinetic studies compared with native GLP-1.
Is research semaglutide approved for human use?
No. Material supplied as a research reference compound is for laboratory use only and is not for human or veterinary use.